Abstract： Objective： To observe the clinical effect and safety of Huisheng capsules combined with ciclosporin soft capsules and thalidomide for myelodysplastic syndrome(MDS) in moderate- risk groups. Methods： A total of 37 cases of moderate-risk patients with MDS were divided into the control group and the treatment group according to the random number table method，18 and 19 cases in each group respectively. Both groups were given transfusion of suspension red blood cells and platelets，anti-infection，and other basic treatments，and the control group was additionally given the oral administration of ciclosporin soft capsules and thalidomide tablets. The treatment group was additionally given the oral administration of Huisheng capsules based on the treatment of the control group. Both groups were treated for two courses， three months being a course. After treatment，the clinical effect and adverse reactions were compared between the two groups. Before and after treatment，the hematological parameters，degree of bone marrow hyperplasia and physical strength were compared between the two groups. Results：The total effective rate of clinical effect was 78.95% in the treatment group，and 61.11% in the control group；no significant difference was found in the comparison of the rate between the two groups(P＞0.05).The total effective rate of curative effect of Chinese medicine syndromes was 84.21% in the treatment group，higher than that of 50.00% in the control group(P＜0.05). After treatment，white blood cell count(WBC)，absolute neutrophil count(ANC)，blood platelet count(BPC)，and hemoglobin(Hb) in the two groups were improved when compared with those before treatment；the improvement of the four indexes above in the treatment group was better than that in the control group， differences being significant(P＜0.05). Before and after treatment， when compared hyperplasia degree of bone marrow between the two groups，there was no significance in differences(P＞0.05). After treatment，Karnofsky scores in the two groups were increased when compared with those before treatment(P＜0.05)；the score in the treatment group was higher than that in the control group(P＜0.05). In the two groups，the degree of adverse reactions was of grade 1 or 2； after symptomatic treatment or decrease in thalidomide content， both groups could have tolerance to medication. Conclusion：In the treatment of MDS in moderate-risk group，the therapy of Huisheng capsules combined with ciclosporin soft capsules and thalidomide can improve Chinese medicine syndromes， peripheral hemogram， and physical strength， without significant adverse reactions.